Challenges in the frontline treatment of patients with chronic lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 5, Issue 1, 2010, Pages 45-51

  Lamanna, Nicole ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Frontline treatment

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; LENALIDOMIDE; PENTOSTATIN; PREDNISONE; RITUXIMAB; THALIDOMIDE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUGS, INVESTIGATIONAL; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 76649132640     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0040-3     Document Type: Review

References (57)

1. G Dighiero P Travade S Chevret, et al. 1991 The French Cooperative Group on CLL: B-cell chronic lymphocytic leukemia: Present status and future directions Blood 78 1901 1914 1912574 1:STN:280:DyaK38%2Fgtl2gug%3D%3D
2. S O'Brien A del Giglio M Keating 1995 Review article: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia Blood 85 307 318 7811987
3. MR Grever KJ Kopecky CA Coltman, et al. 1988 Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia Nouv Rev Fr Hematol 30 457 459 2464793 1:STN:280:DyaL1M7ivVCisw%3D%3D
4. MJ Keating H Kantarjian M Talpaz, et al. 1989 Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 74 19 25 2473795 1:STN:280:DyaL1Mzitlegtw%3D%3D
5. G Juliusson J Liliemark 1993 High complete remission rate from 2-chloro-2'deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count J Clin Oncol 11 679 689 8097528 1:STN:280:DyaK3s3ktVWqsw%3D%3D
6. A Saven RH Lemon M Kosty, et al. 1995 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia J Clin Oncol 13 570 574 7884417 1:STN:280:DyaK2M7ptVGjtg%3D%3D
7. MR Grever JM Leiby EH Kraut, et al. 1985 Low-dose deoxycoformycin in lymphoid malignancy J Clin Oncol 3 1196 1201 2993534 1:STN:280: DyaL2M3ptF2lsg%3D%3D
8. RO Dillman R Mick 1989 Ross McIntyre OR: Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B J Clin Oncol 7 433 438 2784491 1:STN:280:DyaL1M7nslChtg%3D%3D
9. P McLaughlin AJ Grillo-Lopez BK Link, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D
10. DT Nguyen JA Amess H Doughty, et al. 1999 IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients Eur J Haematol 62 76 82 10052709 1:CAS:528:DyaK1MXht12qsL0%3D
11. A Osterborg MJ Dyer D Bunjes, et al. 1997 Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia J Clin Oncol 15 1567 1574 9193354 1:STN:280:DyaK2szjs1KjtQ%3D%3D
12. W Rowan J Tite P Topley SJ Brett 1998 Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells Immunology 95 427 436 10.1046/j.1365-2567.1998.00615.x 9824507 1:CAS:528:DyaK1cXnsVyhtrw%3D (Pubitemid 28505700)
13. G Dighiero K Maloum B Desablens, et al. 1998 Chlorambucil in indolent chronic lymphocytic leukemia N Engl J Med 338 1506 1514 10.1056/ NEJM199805213382104 9593789 1:CAS:528:DyaK1cXjsVOmurk%3D (Pubitemid 28226278)
14. M Hallek BD Cheson D Catovsky, et al. 2008 Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 12 5446 5456 10.1182/blood-2007-06-093906 18216293 1:CAS:528:DC%2BD1cXnsVOktrk%3D
15. H Dohner S Stilgenbauer A Benner, et al. 2000 Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 1910 1916 10.1056/NEJM200012283432602 11136261 1:CAS:528:DC%2BD3MXktlSlsQ%3D%3D (Pubitemid 32064784)
16. RN Damle T Wasil F Fais, et al. 1999 Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 1840 1847 10477712 1:CAS:528:DyaK1MXlvFCnur0%3D
17. TJ Hamblin Z Davis A Gardiner, et al. 1999 Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 1848 1854 10477713 1:CAS:528:DyaK1MXlvFCnuro%3D
18. A Krober T Seiler A Benner, et al. 2002 VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood 100 1410 1416 12149225 1:CAS:528:DC%2BD38Xmt12iur0%3D
19. MI Del Principe G Del Poeta F Buccisano, et al. 2006 Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia Blood 108 843 861
20. M Crespo F Bosch N Villamor, et al. 2003 ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl J Med 348 1764 1775 10.1056/NEJMoa023143 12724482 1:CAS:528: DC%2BD3sXjtlWqsro%3D (Pubitemid 36514707)
21. LZ Rassenti L Huynh TL Toy, et al. 2004 ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia N Engl J Med 351 893 901 10.1056/NEJMoa040857 15329427 1:CAS:528:DC%2BD2cXntVOqurg%3D (Pubitemid 39096916)
22. National Cancer Institute: Early or delayed fludarabine and rituximab in treating patients with previously untreated chronic lymphocytic leukemia [clinical trial]. Available at: http://www.clinicaltrials.gov/ct2/results?term= NCT00513747. Accessed November 13, 2009.
23. MJ Keating H Kantarjian S O'Brien, et al. 1991 Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 9 44 49 1702145 1:STN:280:DyaK3M%2Fos12ltg%3D%3D
24. KR Rai BL Peterson FR Appelbaum, et al. 2000 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 1750 1757 10.1056/NEJM200012143432402 11114313 1:CAS:528: DC%2BD3cXptVehs7k%3D
25. LE Robertson YO Huh JJ Butler, et al. 1992 Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, immunophenotypic, and molecular analysis Blood 80 29 36 1377051 1:STN:280:DyaK38zgsFentQ%3D%3D
26. M Weiss M Glenn P Maslak, et al. 2000 Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 14 557 582 10.1038/sj.leu.2401892 1:CAS:528:DC%2BD3cXntFOhsbk%3D
27. S O'Brien H Kantarjian M Beran, et al. 1993 Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 82 1695 1700 8400226
28. L Elias D Stock-Novack DR Head, et al. 1993 A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study Leukemia 7 361 365 7680398 1:STN:280:DyaK3s7ovVGgsw%3D%3D
29. M Weiss T Spiess E Berman S Kempin 1994 Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia Leukemia 8 1290 1293 8057664 1:STN:280:DyaK2czjsFeitA%3D%3D
30. S O'Brien HM Kantarjian MC Cortes, et al. 2001 Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19 1414 1420 11230486
31. W Wierda S O'Brien S Wen, et al. 2005 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 4070 4078 10.1200/JCO.2005.12.516 15767647 1:CAS:528:DC%2BD2MXmt1emu74%3D (Pubitemid 46211312)
32. MJ Keating S O'Brien M Albitar, et al. 2005 Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 4079 4088 10.1200/JCO.2005.12.051 15767648 1:CAS:528:DC%2BD2MXmt1emu70%3D (Pubitemid 46211313)
33. IW Flinn JC Byrd C Morrison, et al. 2000 Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 71 75 10891432 1:CAS:528:DC%2BD3cXksVKjsL0%3D
34. N Lamanna MA Weiss PG Maslak, et al. 2009 Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses J Clin Oncol 27 491 497 10.1200/JCO.2008.16.4459 19075280 1:CAS:528:DC%2BD1MXivFyjtbw%3D This study demonstrated that PCR negativity confers a 90% likelihood of a 5-year or greater duration of complete response
35. JC Byrd BL Peterson VA Morrison, et al. 2003 Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood 101 6 14 10.1182/blood-2002-04-1258 12393429 1:CAS:528:DC%2BD3sXhtFSrtw%3D%3D (Pubitemid 36025880)
36. JC Byrd K Rai BL Peterson, et al. 2005 Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 49 53 10.1182/blood-2004-03-0796 15138165 1:CAS:528:DC%2BD2MXis1Gksw%3D%3D (Pubitemid 40053062)
37. Hallek M, Fingerle-Rowson G, Fink AM, et al.: Immunochemotherapy with fludarabine, cyclophosphamide, and rituximab versus fludarabine and cyclophosphamide improves response rates and progression free survival of previously untreated patients with advanced chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 325.
38. T Robak J Blonski M Kasznicki, et al. 2000 Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood 96 2723 2729 11023504 1:CAS:528:DC%2BD3cXnt12gsb0%3D
39. T Robak JZ Blonski J Gora-Tybor, et al. 2008 Comparison of cladribine plus cyclophosphamide or fludarabine plus cyclophosphamide in different age groups in previously untreated patients with chronic lymphocytic leukemia (PALG-CLL3 study) [abstract 0407] Haematologica 93 suppl 1 162
40. MA Weiss PG Maslak JG Jurcic, et al. 2003 Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia J Clin Oncol 21 1278 1284 10.1200/JCO.2003.08.100 12663715 1:CAS:528:DC%2BD2cXpsVWqsLs%3D (Pubitemid 46606404)
41. N Lamanna M Kalaycio P Maslak, et al. 2006 Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia J Clin Oncol 24 1575 1581 10.1200/JCO.2005.04.3836 16520464 1:CAS:528:DC%2BD28XjvFykt70%3D (Pubitemid 46638781)
42. NE Kay SM Geyer TG Call, et al. 2007 Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Blood 109 405 411 10.1182/blood-2006-07-033274 17008537 1:CAS:528:DC%2BD2sXivVyktbY%3D (Pubitemid 46105933)
43. TD Shanafelt T Lin SM Geyer, et al. 2007 Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia Cancer 109 2291 2298 10.1002/cncr.22662 17514743 1:CAS:528:DC%2BD2sXmvVKjsLc%3D This study confirmed that the "PCR" regimen is active and tolerable in patients older than 65 years of age (Pubitemid 46801560)
44. WU Knauf T Lissichkov A Aldaoud, et al. 2009 Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 4378 4384 10.1200/JCO.2008.20.8389 19652068 1:CAS:528:DC%2BD1MXht1WisbnO
45. MJ Keating I Flinn V Jain, et al. 2002 Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study Blood 99 3554 3561 10.1182/blood.V99.10.3554 11986207 1:CAS:528:DC%2BD38XjvVGns7o%3D (Pubitemid 34534522)
46. J Lundin E Kimby M Bjorkholm, et al. 2002 A phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 768 773 10.1182/blood-2002-01-0159 12130484 1:CAS:528:DC%2BD38XlvVCltrg%3D (Pubitemid 34832599)
47. P Hillmen AB Skotnick T Robak, et al. 2007 Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 5615 5623 10.1200/JCO.2007.12.9098 1:CAS:528:DC%2BD1cXmsFKltQ%3D%3D
48. S O'Brien HM Kantarjian DA Thomas, et al. 2003 Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 2657 2663 10.1002/cncr.11871 14669286 1:CAS:528: DC%2BD2cXit1yhug%3D%3D (Pubitemid 37509530)
49. K Rai J Byrd BL Peterson RA Larson 2002 A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901 [abstract] Blood 100 205a
50. S Faderl DA Thomas S O'Brien, et al. 2003 Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood 101 3413 3415 10.1182/blood-2002-07-1952 12522009 1:CAS:528: DC%2BD3sXjs1aqs7Y%3D (Pubitemid 36857922)
51. Morrison VA, Peterson FL, Rai KR, et al.: Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia receiving fludarabine-based therapy: A comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 756.
52. Lin TS, Donohue KA, Lucas MS, et al.: Consolidation therapy with subcutaneous alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab induction therapy: Interim safety analysis of CALGB 10101 [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 755.
53. Chen C, Paul H, Xu W, et al.: A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 44.
54. Ferrajoli A, O'Brien S, Wierda W, et al.: Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:abstract 45.
55. Surveillance, Epidemiology, and End Results Program: Median age of cancer patients at diagnosis, 2002-2006 by primary cancer site, race and sex. Bethesda, MD: National Cancer Institute; 2006. Available at http://seer.cancer. gov/csr/1975-2006/results-single/sect-01-table.11-2pgs.pdf. Accessed October 19, 2009.
56. A Ferrajoli S O'Brien W Wierda, et al. 2005 Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients Leuk Lymphoma 46 suppl 1 S86
57. BF Eichhorst R Busch S Stilgenbauer, et al. 2009 First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 3382 3391 10.1182/blood-2009-02-206185 19605849 1:CAS:528:DC%2BD1MXhtlensb7N This important paper confirms that fludarabine does not result in a major clinical benefit in patients older than 65 years of age, versus treatment with chlorambucil